| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $345.0M | +239.4% |
| SG&A Expense | $48.4M | -1.8% |
| Operating Income | -$393.3M | -160.6% |
| Pre-tax Income | -$359.6M | -227.1% |
| Income Tax | $1K | +0.0% |
| Net Income | -$359.6M | -227.1% |
| EPS (Basic) | -$3.19 | -215.8% |
| EPS (Diluted) | -$3.19 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $165.8M | +521.6% |
| Current Assets | $715.6M | -21.1% |
| Total Assets | $715.7M | -21.2% |
| Current Liabilities | $76.7M | +179.7% |
| Total Liabilities | $76.7M | +173.4% |
| Stockholders' Equity | $639.1M | -27.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$278.7M | -217.4% |
| Investing Cash Flow | $341.4M | +161.7% |
| Financing Cash Flow | $76.4M | -87.5% |
| -215.8% |